Analysts have not been kind to Healthpeak Properties in recent months. In early April, Citigroup analyst Michael Griffin downgraded Healthpeak Properties from Buy to Neutral, while announcing a price target of $23. Griffin cited its heavy concentration of life science properties in San Francisco, an area that has recently seen declines in other sectors, such as tech.